<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65428">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886638</url>
  </required_header>
  <id_info>
    <org_study_id>248-13</org_study_id>
    <secondary_id>ACTRN12613000570785</secondary_id>
    <nct_id>NCT01886638</nct_id>
  </id_info>
  <brief_title>Determining the Effect of Abacavir on Platelet Activation</brief_title>
  <official_title>Determining the Effect of Abacavir on Platelet Activation in Virologically Suppressed HIV Positive Men: an Open Label Interventional Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayside Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayside Health</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      HIV positive patients have a two fold increased risk of developing cardiovascular disease
      (such as heart attacks and strokes). Cardiovascular disease appears to be due in part to
      both HIV and the side effects from anti-HIV medications.

      Abacavir (an important component of current HIV treatment regimens) is one medication shown
      to be associated with an increase the risk of heart attacks in some studies. The mechanism
      by which abacavir does this is unknown.

      We hypothesise that abacavir is leading to heart disease by interacting with platelets,
      which then form blood clots within the arteries supplying the heart, the subsequent blockage
      of the artery causing a heart attack.

      This study aims to determine if abacavir increases the activity (or &quot;stickiness&quot;) of
      platelets, and thus provide evidence as to how it may be promoting heart attacks.

      It will consist of 23 HIV positive men who currently have well controlled HIV. Participants
      will take abacavir for 15 days in addition to their usual anti-HIV medications. A blood
      sample to assess platelet activity will be taken at baseline, following the 15 days of
      therapy (i.e. at the time of maximal abacavir effect) and again after a 28 day washout
      period (to determine if any effects are reversible).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Phosphorylated Vasodilator Stimulated Phosphoprotein (P-VASP) assay</measure>
    <time_frame>Baseline, day 15 and day 48</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet aggregation</measure>
    <time_frame>Baseline, Day 15 and day 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the degree of platelet aggregation in response to collagen related peptide and thrombin receptor-agonist peptide</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet specific collagen receptor glycoprotein VI (GPVI)</measure>
    <time_frame>Baseline, Day 15 and Day 48</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measurement of the expression and shedding of platelet specific collagen receptor GPVI</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>HIV</condition>
  <condition>Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>Abacavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abacavir 600mg (as two 300mg tablets) once daily for 15 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abacavir</intervention_name>
    <arm_group_label>Abacavir</arm_group_label>
    <other_name>Ziagen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years of age

          -  Male

          -  HIV positive

          -  Stable non-abacavir containing anti-retroviral regimen

          -  Undetectable HIV Viral load

        Exclusion Criteria:

          -  HLA-B*57*01 allele positivity

          -  Previous allergy to abacavir

          -  Known cardiovascular disease

          -  High Baseline cardiovascular risk (Framingham risk score &gt; 20%)

          -  Current or recent antiplatelet therapy

          -  Pre-existing platelet or bleeding disorder (i.e. Thrombophilia, Thrombocytopenia, Von
             willebrands disease, Haemophilia)

          -  Significant Chronic liver disease

          -  Current Methadone use
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Hoy, MBBS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred health, Monash University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Janine Trevillyan, MBBS FRACP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Alfred Health, Monash university</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Hoy, MBBS, FRACP</last_name>
    <phone>+61 3 90762000</phone>
    <email>jennifer.hoy@monash.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janine Trevillyan, MBBS, FRACP</last_name>
    <phone>+61 3 90762000</phone>
    <email>janine.trevillyan@monash.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alfred Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jennifer Hoy, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janine Trevillyan, MBBS FRACP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>June 24, 2013</lastchanged_date>
  <firstreceived_date>June 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Platelets</keyword>
  <keyword>HIV</keyword>
  <keyword>Cardiovascular disease</keyword>
  <keyword>Acute myocardial infarction</keyword>
  <keyword>Abacavir</keyword>
  <keyword>Antiretrovirals</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abacavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
